The 74-Page Masterwork That Mapped Every Disease the Endocannabinoid System Could Treat

74 Pages, 15 Diseases, One System

Pál Pacher, Sándor Bátkai, and George Kunos were Hungarian-born pharmacologists working at the NIH. Pacher — who would go on to become one of the most highly cited researchers in the world (h-index 137, over 68,000 citations) — had trained in cardiovascular physiology. Kunos, the lab chief, was NIAAA's Scientific Director. Their primary expertise wasn't cannabis. It was how lipid signaling systems affect the heart, the liver, and metabolism.

That perspective is what made the review different. They didn't approach the endocannabinoid system as a cannabis-research team studying drug effects. They approached it as pharmacologists asking: where in the body does this system matter, and how can we make drugs that target it?

The answer was: everywhere.

Not About Cannabis

Myth vs. Reality

✕Myth

The endocannabinoid system is the body's response to cannabis — it matters mostly for understanding how marijuana works.

✓Reality

The ECS is a fundamental regulatory system involved in obesity, cardiovascular disease, liver fibrosis, bone metabolism, cancer, immune disorders, neurodegeneration, and more. Cannabis research led to its discovery, but the system's importance extends far beyond any recreational or medicinal use of the plant.

The Evidence

The Pacher 2006 review documents endocannabinoid system involvement in at least 15 disease categories. Most of the therapeutic targets it identifies — obesity, atherosclerosis, osteoporosis, hepatic fibrosis — have nothing to do with cannabis use. The ECS regulates energy balance, inflammation, cell death, and tissue remodeling throughout the body.

Pacher et al. (2006), Pharmacol Rev 58:389-462

This distinction matters. When people hear "endocannabinoid system," they think "the thing cannabis activates." But the ECS existed for hundreds of millions of years before cannabis plants evolved. It regulates energy balance in every cell. It modulates immune responses in every tissue. It fine-tunes synaptic transmission in every brain circuit. Cannabis happens to contain molecules that interact with it — but the system wasn't built for cannabis any more than opioid receptors were built for poppy plants.

The Pacher review was the first document to comprehensively demonstrate the scope of that distinction.

The Map of Everything the ECS Touches

The scope is staggering. The review wasn't an overview of "what cannabis does" — it was a systematic accounting of every tissue in the body where endocannabinoid signaling had been shown to play a physiological or pathological role. The endocannabinoid system isn't a brain system that happens to exist elsewhere. It's a body-wide regulatory network that happens to be densest in the brain.

For readers coming from the cannabis side, this reframing is essential. When you use cannabis, you're not activating a niche pathway. You're flooding one of the most widespread signaling systems in human biology — which is why the effects touch everything from appetite to heart rate to mood to memory to pain perception simultaneously.

Three Roads to Medicines

The review's lasting contribution wasn't just the disease map. It was a pharmacological framework — three strategies for making drugs that target the endocannabinoid system, each designed to avoid the problems of simply giving people THC.

The logic of each strategy was sound. The preclinical evidence supporting each was extensive. In 2006, the field was more optimistic about endocannabinoid drug development than it had ever been — or would be again.

What Actually Happened

The decade after this review was published tested every one of those strategies. The results were humbling.

Strategy 1 (Block CB1) produced rimonabant — a drug that worked beautifully for weight loss but caused depression and suicidal ideation because CB1 receptors are woven into the brain's mood and reward circuitry. You can't block the most abundant receptor in the brain without psychiatric consequences. Approved in Europe in 2006, withdrawn by 2008. The FDA never approved it.

Strategy 2 (Boost endocannabinoids) seemed safer — you're amplifying the body's own signals rather than introducing a foreign molecule. But in January 2016, a Phase 1 trial of BIA 10-2474 (a FAAH inhibitor) at a contract research organization in Rennes, France, resulted in the death of one healthy volunteer and hospitalization of five others with brain hemorrhages. The compound turned out to have off-target effects unrelated to FAAH. It was the worst clinical trial disaster in France in decades.

Strategy 3 (Activate CB2) was supposed to be the safest — non-psychoactive, anti-inflammatory, pain-relieving. Preclinical data in animals was consistently impressive. But when CB2 agonists reached human trials, they failed. LY2828360 showed no significant pain reduction in osteoarthritis. Species differences in CB2 expression patterns — the receptor is distributed differently in humans than in rodents — likely explain the translation failure.

Why This Paper Still Matters

The three strategies didn't fail because the review was wrong. They failed because the endocannabinoid system is more nuanced than first-generation drugs could handle. Blocking CB1 everywhere in the brain is too crude. Globally inhibiting FAAH needs exquisite selectivity. CB2 biology differs between species in ways nobody anticipated in 2006.

But the framework holds. Current drug development still follows the review's logic — just with more precision:

• Peripherally-restricted CB1 antagonists that stay out of the brain, targeting metabolic disease without psychiatric risk
• MAGL inhibitors that boost 2-AG rather than anandamide, with fewer off-target concerns than FAAH inhibitors
• Allosteric modulators that fine-tune CB1 signaling rather than blocking it completely
• Combination approaches using low-dose cannabinoids with other therapeutic agents

And then there was Epidiolex — CBD approved for epilepsy in 2018 — which came from a different direction entirely. Not a synthetic molecule targeting a specific ECS component, but a plant-derived compound with complex, multi-target pharmacology. Sometimes the plant knows something the drug designers haven't figured out yet.

“Modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions.”

Frequently Asked Questions

Why is a review paper ranked among the most important studies in cannabis science?

Because it was the first document to comprehensively demonstrate that the endocannabinoid system isn't just about cannabis — it's involved in obesity, cardiovascular disease, neurodegeneration, cancer, bone metabolism, immune disorders, and more. At 74 pages covering 15+ disease categories with nearly 3,000 citations, it became the reference that organized the entire field. Individual discovery papers found pieces; this review assembled the map.

Did the drug strategies proposed in this review actually work?

Each strategy produced valuable knowledge but also significant setbacks. CB1 antagonism (rimonabant) worked for weight loss but caused psychiatric side effects and was withdrawn. FAAH inhibition was promising until a disastrous clinical trial in 2016 killed one volunteer. CB2 agonism worked in animals but has failed in human trials. However, the framework isn't wrong — current drug development uses more precise versions of the same strategies: peripherally-restricted compounds, allosteric modulators, and combination approaches. And CBD's approval for epilepsy in 2018 showed that cannabinoid-based medicines can reach patients through unexpected paths.